INSPIRE Pipeline™ Shield Post Approval Study

Study Overview
=================
Brief Summary
-----------------
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) (Pipeline™ Shield PAS) is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ (Pipeline™ Shield Device) in a real-world post approval setting within the United States.

Detailed Description
-----------------
The INSPIRE Pipeline™ Shield Post Approval Study is an observational, prospective, multi-center, single-arm registry to collect on-label use data in patients undergoing treatment for intracranial aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™ according to the intended use. The primary objective of this study is to evaluate the on-label use of the Pipeline™ Shield Device in patients undergoing treatment for intracranial aneurysms per institutional routine clinical care in a real-world post approval study setting in the U.S. This study is conducted under the Product Surveillance Registry (NCT01524276) and is a sub-study to the therapy specific Neurovascular Product Surveillance Registry (NCT02988128).

Official Title
-----------------
Neurovascular Product Surveillance Registry (INSPIRE) Pipeline™ Flex Embolization Device With Shield Technology™ Post Approval Study (PAS)

Conditions
-----------------
Intracranial Aneurysm

Intervention / Treatment
-----------------
* Device: Treatment of Intracranial Aneurysms


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements. Patient is intended to receive or be treated with an eligible Medtronic product. Patient is consented within the enrollment window of the therapy received, as applicable. Patient or patient's legally authorized representative (LAR) has provided written informed consent using the IRB and Medtronic approved Informed Consent Form and agrees to comply with the study requirements. HIPAA/data protection authorization has been provided and signed by the patient (or patient's LAR). Patient has already been selected for endovascular treatment of the target aneurysm with the Pipeline™ Shield Device as the appropriate treatment per the Pipeline™ Shield Device Instructions For Use (IFU). Exclusion Criteria: Patient who is, or is expected to be, inaccessible for follow-up. Participation is excluded by local law. Patient is currently enrolled or plans to enroll in a concurrent drug/device study that may confound the PSR results (i.e. no required intervention that could affect interpretation of all-around product safety and/or effectiveness). Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. Patient is contraindicated for the device or procedure per the Pipeline™ Shield Device IFU. The Investigator determined that the health of the patient may be compromised by the patient's enrollment. Patient is enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval was obtained from Medtronic.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure. | Incidence at 1-year post-procedure of complete occlusion of the target aneurysm, significant parent artery stenosis ≤ 50%, and no retreatment of the target aneurysm. | 1 year |